Telithromycin + Azithromycin

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Otitis Media, Suppurative

Conditions

Otitis Media, Suppurative, Otitis Media, Purulent

Trial Timeline

Jan 1, 2006 → Jul 1, 2006

NCT ID

NCT00315003

About Telithromycin + Azithromycin

Telithromycin + Azithromycin is a phase 3 stage product being developed by Sanofi for Otitis Media, Suppurative. The current trial status is terminated. This product is registered under clinical trial identifier NCT00315003. Target conditions include Otitis Media, Suppurative, Otitis Media, Purulent.

What happened to similar drugs?

2 of 11 similar drugs in Otitis Media, Suppurative were approved

Approved (2) Terminated (1) Active (8)

🔄ofloxacin otic solution 0.3%Daiichi SankyoPhase 3

🔄levofloxacinJohnson & JohnsonPhase 3

🔄levofloxacin; amoxicillin/clavulanateJohnson & JohnsonPhase 3

🔄V114MerckPhase 3

✅Montelukast + PlaceboMerckApproved

🔄7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccineMerckPhase 3

🔄ZmaxPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00315003	Phase 3	Terminated	Jan 1, 2006	Jul 1, 2006	Otitis Media, Suppurative
NCT00237445	Approved	Terminated	Nov 1, 2005	Sep 1, 2006	Pneumonia
NCT00132951	Approved	Terminated	Oct 1, 2004	Sep 1, 2006	Respiratory Tract Infections

Competing Products

15 competing products in Otitis Media, Suppurative

See all competitors

Product	Company	Stage	Hype Score
piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0%	Yuhan	Phase 1/2	24
ofloxacin otic solution 0.3%	Daiichi Sankyo	Phase 3	40
levofloxacin	Johnson & Johnson	Phase 3	40
levofloxacin; amoxicillin/clavulanate	Johnson & Johnson	Phase 3	40
V114	Merck	Phase 3	40
Montelukast + Placebo	Merck	Approved	43
7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine	Merck	Phase 3	40
Prevenar	Pfizer	Pre-clinical	26
Zmax	Pfizer	Phase 3	40
Observational	Pfizer	Pre-clinical	26
Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine	Pfizer	Approved	43
amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR	Pfizer	Phase 3	40
60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR	Pfizer	Phase 2	35
Telithromycin (HMR3647)	Sanofi	Phase 3	40
telithromycin (HMR3647)	Sanofi	Phase 3	32